Financial Incentives to Improve Quality


Traditionally, hospitals had little financial incentive to improve quality of care. They were paid based on the number of infections treated – even if mistakes occurred or those infections were preventable. With today’s healthcare system moving toward outcomes-based reimbursement, healthcare organizations are being held accountable for hospital-associated infection (HAI) rates.

Centers for Medicare & Medicaid (CMS) initiatives, including its Hospital-Acquired Conditions (HAC) Reduction Program, Hospital Value-Based Purchasing (VBP), Hospital Inpatient Quality Reporting (IQR) and Hospital Readmission Reduction Program (HRRP), have created strong incentives for hospitals to preempt HAIs. These programs also financially penalize hospitals with high-infection rates. In fact, thousands of hospitals subject to HRRP will be docked between 1-and-3 percent in payments this year due to high readmission rates.


As CMS and even private payment systems become more active payers of high-quality healthcare services, hospitals are adopting broader, vigilant infection-control strategies to prevent HAIs. A large part of these strategies include the use of antimicrobial-treated medical devices and surfaces to limit patient exposure to dangerous microorganisms.

Sciessent’s Agion line of antimicrobial technology is embedded in numerous FDA-approved medical devices and surfaces. With clinical data to prove its efficacy, Sciessent’s technology works on the surface of products to attack microbes and inhibit their growth – acting as second line of defense in the war against HAIs.    

Products For Medical Applications



Agion's antimicrobial technology keeps products clean and extends product lifespans using silver and copper. The technology behind Agion continuously resists microbe growth and provides products with built-in protection. Agion Antimicrobial can be applied to virtually any material or surface.